Premium Hibiscus Business Plan — Investment Case and Returns
The return profile, valuation basis and exit assumptions, and what the numbers do and do not support.
Section 21 of 25
Investment Case and Returns
Jump to section
- i. Important Notice and Basis of Preparation
- 01. Executive Summary
- 02. Investment Thesis
- 03. Company and Business Overview
- 04. Problem, Customer Need and Value Proposition
- 05. Products and Services
- 06. Industry Analysis
- 07. Market Analysis
- 08. Competitive Landscape
- 09. Business Model
- 10. Go-to-Market Strategy
- 11. Operating Model
- 12. Management and Organisation
- 13. Strategic Plan
- 14. SWOT Analysis
- 15. Risk Analysis
- 16. ESG and Sustainability Impact
- 17. Implementation Roadmap
- 18. Financial Plan
- 19. Funding Requirement and Structure
- 20. Investment Case and Returns
- 21. Sensitivity and Scenario Analysis
- 22. KPIs and Management Dashboard
- 23. Conclusion and Recommendation
- 24. Appendices
On a 5.5x Year-5 EBITDA exit, the base case returns roughly 3.1x MOIC and a ~29% equity IRR. These are growth-stage returns — earned through a real J-curve and sensitive to the exit multiple, FX and execution.
Returns summary
|
Metric |
Base case |
|---|---|
|
Total equity invested (USD ‘000) |
6,000 |
|
Year-5 EBITDA (USD ‘000) |
3,610 |
|
Exit EV/EBITDA multiple |
5.50x |
|
Exit enterprise value (USD ‘000) |
19,855 |
|
Less: net debt at exit (USD ‘000) |
(1,320) |
|
Equity value at exit (USD ‘000) |
18,535 |
|
MOIC |
3.09x |
|
Equity IRR |
29% |
Table 24. Base-case equity returns on a trade-sale exit.
Valuation triangulation
A discounted-cash-flow cross-check at a 15% USD WACC, appropriate for frontier agribusiness, yields an enterprise value of about USD 4.7m, materially below the exit-multiple valuation. This divergence is an honest and important signal: at a 15% discount rate the intrinsic value is modest and heavily terminal-dependent, because the venture consumes cash through Year 3 before free cash flow turns positive. The equity return is therefore a growth-and-execution return, not a deep-value entry. A lower discount rate (patient or concessional capital) or a strategic-buyer premium at exit lifts the intrinsic value; a compression of frontier multiples reduces it.